Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4572096 | 0.93 | MAPT (0.34) | MAPTLMNAHSP90AA1HTTL3MBTL1 | |
| SCHEMBL2200006 | 0.90 | ACHE (0.35) | MAPTLMNAHTTALDH1A1NTSR1 | |
| SCHEMBL13868743 | 0.89 | MAPT (0.35) | MAPTLMNAHTTL3MBTL1ALDH1A1 | |
| SCHEMBL29453309 | 0.87 | STK10 (0.35) | MAPTLMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL1045266 | 0.87 | STK10 (0.35) | MAPTLMNAHTTMAPK1ALDH1A1 | |
| SCHEMBL1046559 | 0.87 | MEN1 (0.32) | MAPTLMNAHTTTDP1ALDH1A1 | |
| SCHEMBL29453311 | 0.87 | MEN1 (0.32) | MAPTLMNAHTTTDP1ALDH1A1 | |
| SCHEMBL1963472 | 0.86 | DRD2 (0.35) | MAPTLMNAL3MBTL1MAPK1GFER | |
| SCHEMBL24620699 | 0.86 | ACHE (0.35) | MAPTHTTL3MBTL1TDP1MAPK1 | |
| SCHEMBL2018673 | 0.86 | DRD2 (0.32) | MAPTLMNAHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8709308-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2014-04-29 | — | — | US | disclosed |
| US-20140034884-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-02-06 | — | — | US | disclosed |
| US-20140030529-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8308996-B2 | Chromene compound | TOKUYAMA CORPORATION (JP) | 2012-11-13 | — | — | US | disclosed |
| US-20120121934-A1 | CHROMENE COMPOUND | TOKUYAMA CORPORATION (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030529-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | MAPT 161/4885LMNA 3743/4885HSP90AA1 3485/4885 |
| US-20120121934-A1 | CHROMENE COMPOUND | TST, CNOT1, CNOT9 | MAPT 458/4885LMNA 3223/4885HSP90AA1 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.